216 related articles for article (PubMed ID: 18837945)
21. How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer.
Cordero OJ; De Chiara L; Lemos-González Y; Páez de la Cadena M; Rodríguez-Berrocal FJ
Anticancer Res; 2008; 28(4C):2333-41. PubMed ID: 18751415
[TBL] [Abstract][Full Text] [Related]
22. Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications.
Lee G
Cancer Biomark; 2009; 5(3):137-42. PubMed ID: 19407368
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
25. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.
Schwarzenbach H; Alix-Panabières C; Müller I; Letang N; Vendrell JP; Rebillard X; Pantel K
Clin Cancer Res; 2009 Feb; 15(3):1032-8. PubMed ID: 19188176
[TBL] [Abstract][Full Text] [Related]
26. Apoptotic markers in cancer.
Holdenrieder S; Stieber P
Clin Biochem; 2004 Jul; 37(7):605-17. PubMed ID: 15234242
[TBL] [Abstract][Full Text] [Related]
27. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor.
Guo Q; Zhang B; Dong X; Xie Q; Guo E; Huang H; Wu Y
Pancreas; 2009 Apr; 38(3):e75-9. PubMed ID: 19276866
[TBL] [Abstract][Full Text] [Related]
28. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
29. [Tumor markers (advances and limits)].
Gomes FR
Acta Med Port; 1997 Jan; 10(1):75-80. PubMed ID: 9245182
[TBL] [Abstract][Full Text] [Related]
30. A single exposure to hyperbaric oxygen increases levels of circulating nucleosomes but does not induce mononuclear cell apoptosis in divers.
Weber SU; Koch A; Siekmann U; Neitzel C; Stüber F; Hoeft A; Schröder S
Undersea Hyperb Med; 2009; 36(2):117-25. PubMed ID: 19462751
[TBL] [Abstract][Full Text] [Related]
31. Nucleosomes in serum of patients with benign and malignant diseases.
Holdenrieder S; Stieber P; Bodenmüller H; Busch M; Fertig G; Fürst H; Schalhorn A; Schmeller N; Untch M; Seidel D
Int J Cancer; 2001 Mar; 95(2):114-20. PubMed ID: 11241322
[TBL] [Abstract][Full Text] [Related]
32. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer.
Japink D; Leers MP; Sosef MN; Nap M
Anticancer Res; 2009 Aug; 29(8):3245-51. PubMed ID: 19661342
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of tumor markers for the control of chemotherapy.
Finek J; Holubec L; Topolcan O; Salvet J; Pikner R; Holdenrieder S; Stieber P; Lamerz R; Holubec Sen L; Svobodova S; Visokai V; Helmichova E
Anticancer Res; 2005; 25(3A):1655-8. PubMed ID: 16035152
[TBL] [Abstract][Full Text] [Related]
34. Circulating nucleosomes as potential biomarkers for cancer diagnosis and treatment monitoring.
Wang H; Wang Y; Zhang D; Li P
Int J Biol Macromol; 2024 Mar; 262(Pt 1):130005. PubMed ID: 38331061
[TBL] [Abstract][Full Text] [Related]
35. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
36. Cell-surface-bound circulating DNA as a prognostic factor in lung cancer.
Tamkovich SN; Litviakov NV; Bryzgunova OE; Dobrodeev AY; Rykova EY; Tuzikov SA; Zav'ialov AA; Vlassov VV; Cherdyntseva NV; Laktionov PP
Ann N Y Acad Sci; 2008 Aug; 1137():214-7. PubMed ID: 18837949
[TBL] [Abstract][Full Text] [Related]
37. SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer.
Moss AC; Jacobson GM; Walker LE; Blake NW; Marshall E; Coulson JM
Clin Cancer Res; 2009 Jan; 15(1):274-83. PubMed ID: 19118055
[TBL] [Abstract][Full Text] [Related]
38. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer.
Dalaveris E; Kerenidi T; Katsabeki-Katsafli A; Kiropoulos T; Tanou K; Gourgoulianis KI; Kostikas K
Lung Cancer; 2009 May; 64(2):219-25. PubMed ID: 18845357
[TBL] [Abstract][Full Text] [Related]
39. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients.
Wong SC; Chan CM; Ma BB; Hui EP; Ng SS; Lai PB; Cheung MT; Lo ES; Chan AK; Lam MY; Au TC; Chan AT
Clin Cancer Res; 2009 Feb; 15(3):1005-12. PubMed ID: 19188172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
